NCT02483767View on ClinicalTrials.gov

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Breast Cancer
Interventions
DRUG

goserelin

Gonadotropin-Releasing Hormone Agonist

DRUG

standard chemotherapy

(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT02483767 - Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | Biotech Hunter | Biotech Hunter